Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 11/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904104 | 0.91 | LPAR1 (0.54) | LPAR1LPAR3 | |
| SCHEMBL4806 | 0.80 | LPAR1 (0.48) | LPAR1LPAR3OPRM1OPRD1OPRK1 | |
| SCHEMBL12988776 | 0.78 | LPAR1 (0.59) | LPAR1LPAR3OPRM1OPRD1OPRK1 | |
| SCHEMBL9904123 | 0.76 | LPAR1 (0.53) | LPAR1LPAR3 | |
| SCHEMBL15261713 | 0.75 | LPAR1 (0.40) | LPAR1LPAR3 | |
| SCHEMBL17077065 | 0.74 | LPAR1 (0.81) | LPAR1LPAR3 | |
| SCHEMBL17077062 | 0.74 | LPAR1 (0.81) | LPAR1LPAR3 | |
| SCHEMBL12988633 | 0.74 | LPAR1 (0.63) | LPAR1LPAR3KCNA3 | |
| SCHEMBL12988841 | 0.74 | LPAR1 (0.63) | LPAR1LPAR3KCNA3 | |
| SCHEMBL9904274 | 0.73 | LPAR1 (0.59) | LPAR1LPAR3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2648714-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012078593-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078593-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | LPAR2, LPAR1, LPAR4 | LPAR1 2/4885LPAR3 6/4885OPRM1 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.